Search clinical trials for: CT041 autologous CAR T-cell injection

Total 1072 results

GlaxoSmithKline

Completed

Redirected Auto T Cells for Advanced Myeloma

Multiple Myeloma

United States
Weijia Fang, MD
Nanjing Blue Shield Biotech Co.,Ltd

Completed

Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer

Ovarian Cancer

China
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Active, not recruiting

Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) (CARPASCIO)

Non-Hodgkin's Lymphoma | B-Cell ALL | B-Cell CLL

United States
German Heart Institute
Miltenyi Biomedicine GmbH

Completed

Bypass Surgery and CD133 Marrow Cell Injection for Treatment of Ischemic Heart Failure (Cardio133)

Congestive Heart Failure | Previous Myocardial Infarction | Coronary Artery Disease With Need for Bypass Surgery | Myocardial Ischemia, Angina Pectoris

Germany
Ministry of Health, Brazil
Ministry of Science and Technology

Terminated

Cell Therapy in Chronic Ischemic Heart Disease

Coronary Artery Disease | Ischemic Heart Disease

Brazil
Xuzhou Medical University

Recruiting

Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Memorial Sloan Kettering Cancer Center
Actinium Pharmaceuticals

Recruiting

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma | B-ALL | DLBCL | DLBCL, Nos Genetic Subtypes | B ALL | Dlbcl-Ci | DLBCL Unclassifiable | DLBCL Activated B-Cell Type | DLBCL Germinal Center B-Cell Type | HGBL | HGBL, Nos

United States
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM

Multiple Myeloma

China
Hrain Biotechnology Co., Ltd.
First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng... and other collaborators

Recruiting

Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
Hrain Biotechnology Co., Ltd.
Shanghai Zhongshan Hospital

Recruiting

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.

Follicular Lymphoma | Diffuse Large B-cell Lymphoma | CD19-positive

China
First Affiliated Hospital of Wenzhou Medical University
Shanghai First Song Therapeutics Co., Ltd

Not yet recruiting

The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases

Systemic Sclerosis | Sjogren's Syndrome | Antiphospholipid Syndrome | ANCA Associated Vasculitis | Systemic Lupus Erythematosus (SLE) | Inflammatory Myopathy

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

Systemic Scleroderma | Dermatomyositis | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Sjogren's Syndrome | SLE (Systemic Lupus)

China
Changhai Hospital
UTC Therapeutics Inc.

Recruiting

Anti-CD70 CAR-T Cell Injection in Patients With CD70-positive Advanced Urologic Neoplasms

CD70-positive Advanced Urologic Neoplasms

China
St. Jude Children's Research Hospital

Recruiting

Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Glioblastoma | Central Nervous System Neoplasms | High Grade Glioma | Ependymoma | Medulloblastoma | Diffuse Midline Glioma, H3 K27M-Mutant | Atypical Teratoid/Rhabdoid Tumor

United States
KK Women's and Children's Hospital
Singapore General Hospital

Recruiting

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute Adult | Lymphoblastic Leukemia in Children | CAR | B-cell Acute Lymphoblastic Leukemia | Large B-cell Lymphoma

Singapore
iCell Gene Therapeutics
iCar Bio Therapeutics

Not yet recruiting

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

High Risk Hematologic Malignancies | Relapsed and/or Refractory Acute Myeloid Leukemia

China
Fudan University
KAEDI

Recruiting

NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Glioblastoma | Hepatocellular Carcinoma | Medulloblastoma | Colon Cancer

China
AffyImmune Therapeutics, Inc.

Recruiting

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

Anaplastic Thyroid Cancer | Relapsed/Refractory Poorly Differentiated Thyroid Cancer

United States
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.

Active, not recruiting

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

China
Sinobioway Cell Therapy Co., Ltd.
The Second Hospital of Anhui Medical University

Active, not recruiting

Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia (EECNTL)

Leukemia

China
Fujian Medical University

Unknown

CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)

Relapsed/Refractory AML

China
Wuhan Union Hospital, China
Wuhan Bio-Raid Biotechnology Co, Ltd. China

Unknown

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | NK/T-cell Lymphoma | Adult T-Cell Lymphoma/Leukaemia

China
Chinese PLA General Hospital

Unknown

A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy

Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T ACI

China
Qingdao Central Hospital
Yake Biotechnology Ltd.

Unknown

CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

Lymphoma, B-Cell | Leukemia, B-Cell | Minimal Disease, Residual

China
Sinobioway Cell Therapy Co., Ltd.

Unknown

Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer (EECSC)

Stomach Neoplasms

China
Peking University
University of Florida

Unknown

CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)

Lymphomas

China, United States
Shanxi Bethune Hospital

Recruiting

Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours

Hematological Malignancy

China
CARsgen Therapeutics Co., Ltd.
RenJi Hospital; First Affiliated Hospital of Zhejiang University; NanJing PLA...

Completed

Chimeric Antigen Receptor T Cells Targeting Glypican-3

Hepatocellular Carcinoma

China
Kenneth Peters, MD
William Beaumont Hospitals

Completed

Autologous Stem Cells for Urinary Incontinence: Single Patient Compassionate Use

Stress Urinary Incontinence

United States
University Hospital, Montpellier

Recruiting

Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies (CAR-T BANK)

Lymphoma and Acute Lymphoblastic Leukemia

France
Shanghai Cell Therapy Group Co.,Ltd
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not yet recruiting

Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Simnova Biotechnology Co.,Ltd.
Chinese PLA General Hospital

Recruiting

The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma

Recurrent Glioblastoma Multiforme

China
Shanghai Mengchao Cancer Hospital
Shanghai Cell Therapy Group Co.,Ltd

Recruiting

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

Solid Tumor

China
Shenzhen University General Hospital

Recruiting

Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (CAR-T)

Refractory Leukemia | Relapse Leukemia

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies (CD5CAR-T)

T-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
KAEDI

Not yet recruiting

NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors

Glioma | Hepatocellular Carcinoma | Colorectal Cancer | Solid Tumor

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

Sarcoma | Ewing Sarcoma | Osteoid Sarcoma

China
Kunming Hope of Health Hospital

Withdrawn

Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL

B-cell Acute Lymphoblastic Leukemia | B-ALL

China
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotechnology Co.,Ltd.; The First Affiliated Hospital of USTC...

Terminated

Study of LUCAR-20S in Patients With R/R NHL

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma

China
Chinese PLA General Hospital

Unknown

Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.

Solid Tumor, Adult

China
Peking University

Unknown

MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma

Lymphoma

China
Allife Medical Science and Technology Co., Ltd.

Unknown

Study of BCMA CAR-T in Multiple Myeloma

Relapsed and Refractory Multiple Myeloma
Wuhan Union Hospital, China

Not yet recruiting

Study of SYS6020 in BCMA-positive Multiple Myeloma

Multiple Myeloma
The Children's Hospital of Zhejiang University...
Chongqing Precision Biotech Co., Ltd

Recruiting

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus | CAR-T Cell Therapy

China
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
University of Pennsylvania
Prostate Cancer Foundation

Recruiting

TmPSMA-02 in mCRPC

Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies

Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | T-cell Acute Lymphoblastic Leukemia | T Lymphoblastic Leukemia/Lymphoma

China
The First Affiliated Hospital of Soochow University
Affiliated Hospital of Jiangnan University; The Affiliated Nanjing Drum Tower... and other collaborators

Recruiting

CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma

Refractory and Relapsed T Cell Lymphoma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor

Gastric Cancer | Lung Cancer | Osteosarcoma | Neuroblastoma
University College, London

Recruiting

Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 (ALLCAR19)

Leukemia, Lymphoblastic, Acute, Lymphoma

United Kingdom

Search clinical trials for: CT041 autologous CAR T-cell injection

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations